170812-176

Identification of novel EGFR ectodomain mutations based on a large database of clinical circulating cell-free DNA sequencing tests.

Category: 
Tumor Biology
Session Type and Session Title: 
This abstract will not be presented at the 2016 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract Number: 

e23167

Citation: 
J Clin Oncol 34, 2016 (suppl; abstr e23167)
Author(s): 
Christine Elaine Lee, Richard Burnham Lanman, Kimberly C. Banks, Rebecca J Nagy, Stefanie Mortimer, Daniel A. Simon, Darya Chudova, Helmy Eltoukhy, AmirAli Talasaz, Enrique Lastra, Scott Kopetz, John H. Strickler; Guardant Health, Redwood City, CA; Guardant Health, Inc., Redwood City, CA; Hospital Universitario de Burgos, Asociación de La Concepción, BioSequence, Burgos, Spain; The University of Texas MD Anderson Cancer Center, Houston, TX; Duke University Medical Center, Durham, NC

Abstract Disclosures

Abstract: 

Identification of novel EGFR ectodomain (ECD) mutations based on a database of clinical circulating cell-free DNA sequencing testsBackground: The Cancer Genome Atlas primarily sequenced early stage, treatment-naïve cancers, whereas our laboratory primarily sequences treatment refractory metastatic solid tumors. Circulating cell-free DNA (cfDNA) next generation sequencing (NGS) has enhanced sensitivity, which may aid in the detection of emerging resistant clones. In patients with RAS wild-type metastatic colorectal cancer (mCRC) EGFRECD mutations are associated with acquired resistance to anti-EGFR therapies. Here we report the frequencies of ECD mutations in patients with mCRC. Methods: Guardant360 is a cfDNA NGS test targeting 70 genes with complete exon sequencing for single nucleotide variants (SNVs), including all 28 exons in EGFR. Analytical sensitivity ranges to 0.05% mutant allele fraction (MAF) with analytic specificity for SNVs > 99.9999%. The 25th, 50th and 75thpercentile MAF for all 13,987 patients tested from June 2014 through January 2016 were 0.2%, 0.4% and 2.5%. Results: From 2014-2016 1,347 tests were performed on 1,257 patients with mCRC. Exon 12 EGFR SNVs [median MAF(range)] with > 3 recurrences were: 8 S464X [0.9%(0.1-3.1)]; 18 G465X [0.5%(.1-3.1); 3 K467X [0.3%(.2-1.0)]; 4 I491X [0.9%(0.3-1.6)]; 11 S492X [2.1%(0.3-5.1)]. Two novel EGFR SNVs were: 20 V441X [1.3%(0.1-2.8)]; and 5 S442X [0.2%(.1-2.7)]. Range of EGFR SNVs per case was 1-6, with a single hypermutated case demonstrating many resistance sub-clones: 6 EGFR exon 12 SNVs, and 4 KRAS and 3 NRAS SNVs in codons 12 and 61, and an STRN-ALKfusion at 0.1% MAF. Conclusions: A database of cfDNA NGS results in patients with mCRC revealed EGFR ECD SNVs known to drive anti-EGFR therapy resistance. Two spatially co-located SNVs of unknown significance were discovered, and these occurred in some cases at the highest MAF of EGFR SNVs. This analysis suggests that these two novel SNVs may function as major drivers of clonal resistance.